Hépatite virale chronique C

For patients infected with HCV genotype 3, extending sofosbuvir–ribavirin treatment to 24 weeks resulted in substantially higher rates of response and lower rates of re- lapse

Sarcoidosis associated with pegylated interferon alfa and ribavirin treatment for chronic hepatitis C: a case report and review of the literature. Ribavirin

Studies of antiviral therapy during pregnancy and development of a hepatitis C vaccine are underway.. Infants of mothers infected with HCV should be screened at

Nous rapportons le cas d’une femme de 62 ans atteinte d’une hépatite chronique virale C ayant développé une thrombopénie sévère avec un taux de plaquettes à 1000/mm

Conclusion : Our data indicate that treatment of chronic hepatitis C with PEG-IFN alfa-2b plus weight-based ribavirin results in favourable treatment outcomes in a Belgian cohort

Chronic infection with hepatitis C virus in patients with elevated or persistently normal serum alanine aminotransferase levels: comparison of hepatic histology an response

Genetic variability of hepatitis C virus in chronically infected patients with viral breakthrough during interferon-ribavirin therapy3. Khattab contributed equally to

Hepatic steatosis in patients with chronic hepatitis C virus genotype 2 or 3 does not affect viral response in patients treated with peginterferon alpha-2a (40KD) (PEGASYS)